ERBB2 and neoplasm: The number of FHR4 valences dictates the efficacy of the multimers to selectively and locally activate complement alternative pathway on HER2‐tumour cell surface, leading to complement‐dependent cytotoxicity and complement‐dependent cell‐mediated phagocytosis.